Abstract
The translation of promising preclinical treatments into effective drugs for Alzheimer's disease (AD) has been challenging. One of the most potent risk factors for sporadic AD is carrier status of the epsilon 4 allele of the apolipoprotein E gene (E4). E4 carriers show a differential response to several therapies which are being investigated as AD treatments, including acetylcholinesterase inhibitors and therapeutics with vascular and metabolic targets. The differential treatment responses of E4 carriers may partially explain why some treatments show a null effect in clinical trials. Understanding the reasons behind these responses is not only important for clinical practice, but may also help us elucidate mechanisms for this neurodegenerative disease.
Keywords: Alzheimer's disease, treatments, APOE genotype.
Current Pharmaceutical Design
Title:The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Volume: 21 Issue: 1
Author(s): Angela J. Hanson, Suzanne Craft and William A. Banks
Affiliation:
Keywords: Alzheimer's disease, treatments, APOE genotype.
Abstract: The translation of promising preclinical treatments into effective drugs for Alzheimer's disease (AD) has been challenging. One of the most potent risk factors for sporadic AD is carrier status of the epsilon 4 allele of the apolipoprotein E gene (E4). E4 carriers show a differential response to several therapies which are being investigated as AD treatments, including acetylcholinesterase inhibitors and therapeutics with vascular and metabolic targets. The differential treatment responses of E4 carriers may partially explain why some treatments show a null effect in clinical trials. Understanding the reasons behind these responses is not only important for clinical practice, but may also help us elucidate mechanisms for this neurodegenerative disease.
Export Options
About this article
Cite this article as:
Hanson Angela J., Craft Suzanne and Banks A. William, The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease, Current Pharmaceutical Design 2015; 21 (1) . https://dx.doi.org/10.2174/1381612820666141020164222
DOI https://dx.doi.org/10.2174/1381612820666141020164222 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cerebral Ischemia and Angiogenesis
Current Neurovascular Research Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Alpha 1 Anti-Trypsin: One Protein, Many Functions
Current Molecular Medicine Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Does a Physically Active Lifestyle Attenuate Decline in All Cognitive Functions in Old Age?
Current Aging Science Glucocorticoids, the Etiology of Obesity and the Metabolic Syndrome
Current Alzheimer Research Advancement in Obesity Management: Leptin and Adiponectin Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Current Alzheimer Research Diagnosis of Alzheimer's Disease Based on Deeply-Fused Nets
Combinatorial Chemistry & High Throughput Screening Progranulin Mutations in Ubiquitin-Positive Frontotemporal Dementia Linked to Chromosome 17q21
Current Alzheimer Research Role of the Blood-Brain Barrier in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Alzheimerss Disease, Dementia and Cognitive Decline (Executive Editors: J.E. Starrett, Jr. and G.S. Poindexter)]
Current Pharmaceutical Design Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Tau, Amyloid Beta and Deep Brain Stimulation: Aiming to Restore Cognitive Deficit in Alzheimer's Disease
Current Alzheimer Research Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Neurovascular Complications of Ovarian Hyperstimulation Syndrome (OHSS): From Pathophysiology to Recent Treatment Options
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Brain Cholesterol and its Oxidized Products in Alzheimer's Disease
Current Alzheimer Research